Respiratory syncytial virus

Muñoz, Flor M.; Englund, Janet A.

doi:10.1016/b978-0-12-814582-1.00011-5

Cited by 4 publications

(3 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, Corynebacterium pseudodiphtheriticum a respiratory microbiota, controls antiviral TLR3 response against Respiratory Syncytial Virus (RSV) via increasing T-cell subpopulations, which induces TNFα, IL-6, IFNγ, and IFNβ secretion [204,205]. Munoz and colleagues revealed that although RSV immunoprophylaxis is clinically beneficial for RSV infection specially during the highest respiratory vulnerability period, but it might cause long-term alteration in the respiratory microbiota [206]. The last interaction between RSV and the microbiota hyaluronic acid (HA) is a bacterial component, which have roles in inflammation, tumors, and viral infections caused by viruses like RSV.…”

Section: Respiratory Syncytial Virusmentioning

confidence: 99%

Dual and mutual interaction between microbiota and viral infections: a possible treat for COVID-19

et al. 2020

View full text Add to dashboard Cite

All of humans and other mammalian species are colonized by some types of microorganisms such as bacteria, archaea, unicellular eukaryotes like fungi and protozoa, multicellular eukaryotes like helminths, and viruses, which in whole are called microbiota. These microorganisms have multiple different types of interaction with each other. A plethora of evidence suggests that they can regulate immune and digestive systems and also play roles in various diseases, such as mental, cardiovascular, metabolic and some skin diseases. In addition, they take-part in some current health problems like diabetes mellitus, obesity, cancers and infections. Viral infection is one of the most common and problematic health care issues, particularly in recent years that pandemics like SARS and COVID-19 caused a lot of financial and physical damage to the world. There are plenty of articles investigating the interaction between microbiota and infectious diseases. We focused on stimulatory to suppressive effects of microbiota on viral infections, hoping to find a solution to overcome this current pandemic. Then we reviewed mechanistically the effects of both microbiota and probiotics on most of the viruses. But unlike previous studies which concentrated on intestinal microbiota and infection, our focus is on respiratory system’s microbiota and respiratory viral infection, bearing in mind that respiratory system is a proper entry site and residence for viruses, and whereby infection, can lead to asymptomatic, mild, self-limiting, severe or even fatal infection. Finally, we overgeneralize the effects of microbiota on COVID-19 infection. In addition, we reviewed the articles about effects of the microbiota on coronaviruses and suggest some new therapeutic measures.

show abstract

Section: Respiratory Syncytial Virusmentioning

confidence: 99%

Dual and mutual interaction between microbiota and viral infections: a possible treat for COVID-19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Premature infants and those born from HIV-positive mothers are at high risk of RSV infection, leading to high morbidity and mortality rates in these populations [4,5]. There is currently no licensed vaccine for RSV prevention [6]. Palivizumab (Synagis ® ) is the only prophylactic monoclonal antibody (mAb) treatment available for the prevention of RSV disease, but due to high cost its use is restricted to high-risk infants residing in low-, middle-and high-income countries [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Characterisation of RSV Fusion Proteins from South African Patients with RSV Disease, 2019 to 2020

Mabilo

Mthiyane

Simane

et al. 2022

Viruses

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is classified into RSV-A and RSV-B, which are further classified into genotypes based on variability in the G gene. The fusion (F) protein is highly conserved; however, variability within antigenic sites has been reported. This study aimed to characterise F proteins from RSV strains detected in South Africa from 2019 to 2020. Patients of all ages, from whom respiratory samples were submitted to the National Health Laboratory Service at Charlotte Maxeke Johannesburg Academic Hospital, South Africa during 2019 to 2020, were included. Complete RSV F genes were amplified for next-generation sequencing. MEGA X software was used for phylogenetic analysis. The overall prevalence of RSV was 5.8% (101/1734). Among 101 RSV positive samples only 69.3% (70/101) were available for characterization of the RSV F protein gene. Among cases included for F gene characterisation, viral co-infections were observed in 50% (35/70) and 25.7% (18/70) were admitted to intensive care units (ICU). About 74.2% (23/31) of F gene sequences cluster with other African NA1/ON1 genotypes. At antigenic site I, the V384I mutation was replaced by V384T in South African strains. The S275F mutation was seen in a single South African strain. The N120 N-linked glycosylation site was present in 25.8% (8/31) of RSV-A F proteins described in this study. For the first time, we detected the rare S275F mutation that is associated with palivizumab resistance.

show abstract

“…Pulmonary infection by the respiratory syncytial virus (RSV) is a large burden on human health ( 1 ). Airway epithelial cells lining the respiratory tract render them primary targets for RSV replication, mounting the earliest elements of the host defense via the secretion of cytokines or chemokines ( 2 ).…”

mentioning

confidence: 99%

Nei-like DNA glycosylase 2 selectively antagonizes interferon-β expression upon respiratory syncytial virus infection

Pan¹,

Xue²,

Wang³

et al. 2023

Journal of Biological Chemistry

View full text Add to dashboard Cite

Respiratory syncytial virus

Cited by 4 publications

References 62 publications

Dual and mutual interaction between microbiota and viral infections: a possible treat for COVID-19

Dual and mutual interaction between microbiota and viral infections: a possible treat for COVID-19

Characterisation of RSV Fusion Proteins from South African Patients with RSV Disease, 2019 to 2020

Nei-like DNA glycosylase 2 selectively antagonizes interferon-β expression upon respiratory syncytial virus infection

Contact Info

Product

Resources

About